LUSEFI

This brand name is authorized in Japan

Active ingredients

The drug LUSEFI contains one active pharmaceutical ingredient (API):

1 Luseogliflozin UNII C596HWF74Z - LUSEOGLIFLOZIN

Luseogliflozin lowers plasma glucose by inhibiting the activity of sodium-glucose cotransporter 2 (SGLT2) which is involved in reabsorption of glucose at renal proximal tubules and promoting the excretion of excessive glucose in blood into urine. Read about Luseogliflozin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LUSEFI Film-coated tablet	Web Search	MPI, Generic

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A10BK07		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Discover more medicines within A10BK07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: JP	医薬品医療機器総合機構	Identifier(s): 3969020F1020, 3969020F2026, 3969020F3022